Atrial Fibrillation: A Review of Recent Studies with a Focus on Those from the Duke Clinical Research Institute

Table 2

Hazard ratios with 95% CI for novel oral anticoagulants compared with warfarin [37].

	RE-LY*	ROCKET-AF	ARISTOTLE
Stroke and systemic embolism	0.65 (0.52–0.81)	0.88 (0.75–1.03)	0.79 (0.66–0.95)
Ischemic or unspecified stroke	0.76 (0.60–0.98)	0.91 (0.73–1.13)	0.92 (0.74–1.13)
Hemorrhagic stroke	0.26 (0.14–0.49)	0.59 (0.37–0.93)	0.51 (0.35–0.75)
Myocardial infarction	1.27 (0.94–1.71)	0.81 (0.63–1.06)	0.88 (0.66–1.17)
All-cause mortality	0.88 (0.77–1.00)	0.85 (0.70–1.02)	0.89 (0.80–0.998)
Major bleeding	0.93 (0.81–1.07)	1.04 (0.90–1.20)	0.69 (0.60–0.80)
Gastrointestinal bleeding	1.50 (1.19–1.89)	1.47 (1.20–1.81)	0.89 (0.70–1.15)
Intracranial bleeding	0.40 (0.27–0.60)	0.67 (0.47–0.93)	0.42 (0.30–0.58)

*HR presented are for the 150 mg twice daily dose of dabigatran.